GTC to receive $12.3 million from LFB
This article was originally published in Scrip
Executive Summary
GTC Biotherapeutics is to receive $12.3 million from development partner LFB Biotechnologies, and could receive an additional $6.4 million if LFB exercises its share purchase option.